I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days 1 2 22 36 50 64 92 E V A L U A.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

PARAMOUNT: phase III study of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC.

Questions and answers about PARAMOUNT: phase III study of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC.

21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.

Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.

Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.

Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer.

A single-arm phase II trial in p treated with C, D and B (15 mg/kg) every 3 weeks followed by B showed a promising efficacy, in terms of progression free.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

Intergroup trial CALGB 80101

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.

ESMO 2011 Lung Cancer AVAPERL Study Authors: Dr. Sunil Verma Date posted: September 28 th, 2011.

A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma.

Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Phase I/II Trial of Docetaxel plus Oxaliplatin and 5-Fluorouracil (D-FOX) in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer Jaffer.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.

A paradigm shift in the treatment of advanced lung cancer: survival and symptom benefits with Tarceva Tudor-Eliade Ciuleanu Cancer Institute Ion Chiricuta.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

The Combination of Bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) is highly active in advanced colorectal.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

A Phase II Study of Sorafenib Combining with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.

Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.

RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Alessandra Gennari, MD PhD

BIBF 1120 (Nintedanib) in platinum-resistant ovarian cancer:

Results of Definitive Radiotherapy in Anal Canal Carcinoma

TERAPIA SEQUENZIALE E/O DI MANTENIMENTO DOPO UNA PRIMA LINEA: ANCORA UN TRATTAMENTO SPERIMENTALE? Paolo Bidoli S.C. Oncologia Medica A.O. San Gerardo Monza.

Phase II Study of Docetaxel (D) and Oxaliplatin (O) in Recurrent Metastatic Transitional Cell Carcinoma of the Bladder Davar D1, Appleman LA1, Friedland.

PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.

Gajria D et al. Proc SABCS 2010;Abstract P

CCO Independent Conference Coverage

Compassionate People World Class Care

Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Intervista a Lucio Crinò

Nab-paclitaxel nel NSCLC avanzato

EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.

LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.

A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel.

Treatment of Stage III Non-small Cell Lung Cancer

Presentation transcript:

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A T I O N IASLC, 15 TH WCLC 2013; Sydney: # 1010 I I I.- R E S U L T S: I I I. A.- Patients Characteristics (n = 53) C O N C L U S I O N S:  CONCURRENT CHEMORADIATION WITH BI-WEEKLY DOCETAXEL AND CISPLATIN AND THORACIC RADIOTHERAPY, AFTER ONE CYCLE OF INDUCTION CHEMOTHERAPY WITH D-C, IS A FEASIBLE TREATMENT OPTION FOR IRRESECABLE LOCALLY ADVANCED STAGE III A – III B NON SMALL CELL LUNG CANCER.  AN GOOD CLINICAL ACTIVITY, TOLERABILITY AND MEDIAN OVERALL SURVIVAL WERE OBSERVED.  AN ACCEPTABLE LONG TERM SURVIVAL WAS ACHIEVED. I I I. B.- T O X I C I T Y (per p) Median age (range), years 59,4 (34 – 75) Sex Male Female 47 (88 %) 6 (12 %) ECOG (Performance Status) (31,4 %) 36 (68.6 %) Histology Squamous Adenocarcinoma Large cell 28 (52.8 %) 18 (33.9 %) 7 (13.3 %) Stage III A T1-3 N2 15 (28.3 %) Stage III B T4 N0-2 T1-3 N3 T4 N3 27 (50.9 %) 7 (13.3 %) 4 (7.5 %) Weight loss < 5%6 (11.3 %) Evaluable Response Toxicity 53 (100 %) TOXICITIESg 1-2g 3 neutropenia anemia62.20 esophagitis pneumonitis320 n/vomiting20.70 fatigue hospitalizations: febrile neutropenia: 2 p g3 Esophagitis: 2 p I I I. D.- T H E S U R V I V A L C U R V E S (KAPLAN-MEIER): “CONCURRENT CHEMORADIATION (CChRT) FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY FROM GALICIAN LUNG CANCER GROUP” J. Casal 1, C. Ponte 2, C. Senín 1, B. Campos 3, XL. Firvida 4, M. Carmona 5, E. Hernández 6, MD. López 7, I. Formoso 2, M. Lázaro 1, S. Vázquez 3, MC. Areses 4, C. Rodríguez 5, C. Pena 8, MJ. Villanueva 1 1 Sº Oncoloxía Medica (OM) Complexo Hospitalario Universitario (C. H. U.) de Vigo, Spain; 2 Sº Oncoloxia Radioterápica (OR) C.H. U. de Santiago, Spain; 3 Sº OM H. U. Lucus Augusti de Lugo, Spain; 4 Sº OM. C.H. U. de Ourense, Spain; 5 Sº OM C.H. U. de Santiago, Spain; 6 Sº OR C.H.U. de Vigo, Spain; 7 Sº OR C.H.U. de Ourense, Spain; 8 Sº OM C.H. de Pontevedra, Spain. Induction chemotherapy C C h R T follow - up b) CChRT: 50 p: D-C doses: 203 (3.8 per p) mean RT doses: 64,6 Gy ( ) RESPONSEP%95% CI CR611.3 PR OR SD47.6 PD611.3 I I I. C.- E F F I C A C Y (%) : a) INDUCTION D-C: 53 cycles (1 per p) SURVIVALMEDIAN (months) 95% CI1 year % 2 years % 3 Years % OS SLPR ,8n.a. TOXICITIESg 1-2g 3-4 neutropenia1.815 anemia11.30 n/vomiting diarrhea fatigue35.80 stomatitis hospitalisations: febrile neutropenia: 1 p g3 diarrhea: 1 p I.- B A C K G R O U N D: I.- B A C K G R O U N D:  Combined cytotoxic chemotherapy and radiation therapy is established as the standard treatment for patients with medically inoperable or technically unresectable stage III NSCLC.  Multiple randomized studies and meta-analyses demonstrate that CChRT results in improved survival compared with sequential chemo-radiotherapy or radiotherapy alone. A clearly superior regimen has not identified.  Docetaxel (D) has been shown to posess good single activity against NSCLC as well as radiosensiziting properties both alone and sinergistically with Cisplatin (C).  The aim of our study was to evaluate the effectiveness and toxicities of CChRT with bi-weekly Docetaxel (D) and Cisplatin (C) and thoracic radiotherapy, after one cycle D-C induction chemotherapy. I I. A.- M A T E R I A L A N D M E T H O D S: I I. A.- M A T E R I A L A N D M E T H O D S:  SELECTIVE  SELECTIVE CRITERIA: - Age < 75 years. - Histological confirmation. - Stage: IIIA – IIIB (except pleural effusion T4) (AJCC’97). - Evaluable or measurable disease. - PS 0-1 (WHO grade). - Normal organic functions; - FEV1 > 1.1 litres. V20 < 25%. - Weight loss < 5 %. - No previous treatment or serious underlyne disease.  50 patients (p) with locally advanced NSCLC were included from June/2009 to July/2012.  MEDIAN FOLLOW-UP: 17,8 Months. A B S T R A C T T E X T Background: Combined cytotoxic chemotherapy and radiation therapy is established as the standard treatment for patients with medically inoperable or technically unresectable stage III NSCLC. Multiple randomized studies and meta-analyses demonstrate that CChRT results in improved survival compared with sequential chemo-radiotherapy or radiotherapy alone. The aim of our study was to evaluate the effectiveness and toxicities of CChRT with bi- weekly Docetaxel (D) and Cisplatin (C) and thoracic radiotherapy, after one cycle D-C induction chemotherapy. Methods: Between May 2009 and November 2012, 53 chemo-naive p with histologically confirmed inoperable locally advanced NSCLC, stage IIIAN2/IIIB (no pleural T4), PS 0-1 and adequate lung function (FEV1 > 1.1, V20 < 25%) were included: one cycle of D 75 mg/m2 on day 1 and C 40 mg/m2 days 1-2 followed at 21 days by CChRT with bi-weekly D 40 mg/m2 and C 40 mg/m2 for four courses, during conformal thoracic radiotherapy (66 Gys, 180 cGy/day). The primary objective was overall survival (OS); secondary objectives were progression free survival (PFS), response rate (RR) and toxicity. Median follow-up: 17,8 months. Results: The p characteristics were: mean age 59,4 years (34-75); male/female 47/6; ECOG PS 0/1 in 17/36 p; squamous/adeno/large cell carcinoma: 53%/34%/13%; stage IIIAN2 15 p (28.3%) and stage IIIB 38 p (71.7%). All p were evaluable for response and toxicity. RR: 6 CR, 37 PR (RR 81.8%; 95% CI:71-92), 4 SD (7.6%) and 6 PD (11.3%). The median PFS was 14 months (95% CI:11-17) and median OS was 21 months (95% CI:9-32). The PFS at 1/2 years were 55%/32% and the OS at 1/3 years were 82%/50%. A total of 53 cycles of D-C induction chemotherapy were given; main toxicities (NCI-CTC 3.0) per p Grade (g) 1-2/3-4 (%) were as follows: neutropenia 1.8/15; anemia 11.3/0; nausea/vomiting 26.4/1.8; diarrhea 22.6/3.7; fatigue 35.8/0; there were three episodes of hospitalization: febrile neutropenia 2 p and g3 diarrhea 1p. Main toxicities per p in CChRT (D-C doses: 203, 3.8 per p; mean doses RT: 64,6 Gys) were g1-2/3 (%): neutropenia 28.3/5.6; anemia 62.2/0; esophagitis 50.9/3.7 and pneumonitis 32/0; nausea/vomiting 20.7/0; fatigue 37.7/3.7; there were four episodes of hospitalization: febrile neutropenia, 2 p and g3 esophagitis, 2 p. Conclusion: CChRT with bi-weekly Docetaxel and Cisplatin and thoracic radiotherapy is a feasible treatment option for inoperable locally advanced stage III NSCLC, showing good clinical efficacy and tolerability with acceptable long-term survival.  PRIMARY OBJECTIVE: Overall survival (Kaplan-Meier)  SECONDARY: Progresion free survival, (Kaplan-Meier). Response rate (Recist). Toxicity (CTC-NCI v3.0 and RTOG.